Alkem Laboratories (NSE:ALKEM) Scaled Net Operating Assets: N/A (As of Mar. 2026)


NSE:ALKEM Alkem Laboratories Ltd NSE:ALKEM
96 GF Score
Price ₹5,567.50
GF Value ₹6,078.06
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Alkem Laboratories Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Alkem Laboratories's operating assets for the quarter that ended in Mar. 2026 was ₹158,802 Mil. Alkem Laboratories's operating liabilities for the quarter that ended in Mar. 2026 was ₹44,769 Mil. Alkem Laboratories's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, Alkem Laboratories's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


Alkem Laboratories Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Alkem Laboratories's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkem Laboratories Scaled Net Operating Assets Chart

Alkem Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.69 0.57 0.64 0.65

Alkem Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:ALKEM vs ZTS, UTHR: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkem Laboratories Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's Scaled Net Operating Assets falls into.


NSE:ALKEM
96GF Score
Alkem Laboratories Ltd NSE:ALKEM
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkem Laboratories Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Alkem Laboratories's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(158802.4-44768.8)/176911
=0.64

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=208729.7 - 49927.3
=158802.4

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=65240.4 - 8692.3 - 11779.3
=44768.8

Alkem Laboratories's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(158802.4-44768.8)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=208729.7 - 49927.3
=158802.4

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=65240.4 - 8692.3 - 11779.3
=44768.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?

Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued. The current stock price of ₹5,567.50 is trading 8.4% below its estimated GF Value™ of ₹6,078.06. GuruFocus considers Alkem Laboratories to be Fairly Valued.

Key valuation signals for NSE:ALKEM:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹6,078.06 vs. price of ₹5,567.50 (8.4% below fair value)
  • GF Score™: 96/100 with 1 warning sign

No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alkem Laboratories Business Description

Other Exchanges 539523:India
Address Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
96GF Score

Get the complete analysis for NSE:ALKEM

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5,567.50
Price
₹6,078.06
GF Value